table of content
1 Introduction to Research & Analysis Reports
1.1 Non-Insulin Therapies for Diabetes Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Insulin Therapies for Diabetes Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Insulin Therapies for Diabetes Overall Market Size
2.1 Global Non-Insulin Therapies for Diabetes Market Size: 2021 VS 2028
2.2 Global Non-Insulin Therapies for Diabetes Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Insulin Therapies for Diabetes Players in Global Market
3.2 Top Global Non-Insulin Therapies for Diabetes Companies Ranked by Revenue
3.3 Global Non-Insulin Therapies for Diabetes Revenue by Companies
3.4 Top 3 and Top 5 Non-Insulin Therapies for Diabetes Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-Insulin Therapies for Diabetes Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Players in Global Market
3.6.1 List of Global Tier 1 Non-Insulin Therapies for Diabetes Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Non-Insulin Therapies for Diabetes Market Size Markets, 2021 & 2028
4.1.2 Alpha-glucosidase Inhibitors
4.1.3 Amylin Agonists
4.1.4 Biguanides
4.1.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
4.1.6 Glinides / Meglitinides
4.1.7 GLP-1 Analogs / GLP-1 Agonists
4.1.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
4.1.9 Sulfonylureas
4.1.10 Thiazolidinediones
4.1.11 Others
4.2 By Type - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
4.2.1 By Type - Global Non-Insulin Therapies for Diabetes Revenue, 2017-2022
4.2.2 By Type - Global Non-Insulin Therapies for Diabetes Revenue, 2023-2028
4.2.3 By Type - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Insulin Therapies for Diabetes Market Size, 2021 & 2028
5.1.2 Monitoring
5.1.3 Diagnosis
5.1.4 Treatment
5.1.5 Others
5.2 By Application - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
5.2.1 By Application - Global Non-Insulin Therapies for Diabetes Revenue, 2017-2022
5.2.2 By Application - Global Non-Insulin Therapies for Diabetes Revenue, 2023-2028
5.2.3 By Application - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Non-Insulin Therapies for Diabetes Market Size, 2021 & 2028
6.2 By Region - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
6.2.1 By Region - Global Non-Insulin Therapies for Diabetes Revenue, 2017-2022
6.2.2 By Region - Global Non-Insulin Therapies for Diabetes Revenue, 2023-2028
6.2.3 By Region - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.3.2 US Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.3.3 Canada Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.3.4 Mexico Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.4.2 Germany Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.3 France Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.4 U.K. Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.5 Italy Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.6 Russia Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.7 Nordic Countries Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.8 Benelux Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.5.2 China Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.3 Japan Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.4 South Korea Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.5 Southeast Asia Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.6 India Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.6.2 Brazil Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.6.3 Argentina Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.7.2 Turkey Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7.3 Israel Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7.4 Saudi Arabia Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7.5 UAE Non-Insulin Therapies for Diabetes Market Size, 2017-2028
7 Players Profiles
7.1 GSK
7.1.1 GSK Corporate Summary
7.1.2 GSK Business Overview
7.1.3 GSK Non-Insulin Therapies for Diabetes Major Product Offerings
7.1.4 GSK Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.1.5 GSK Key News
7.2 Eli Lilly
7.2.1 Eli Lilly Corporate Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Major Product Offerings
7.2.4 Eli Lilly Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.2.5 Eli Lilly Key News
7.3 Sumitomo Dainippon Pharma
7.3.1 Sumitomo Dainippon Pharma Corporate Summary
7.3.2 Sumitomo Dainippon Pharma Business Overview
7.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Major Product Offerings
7.3.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.3.5 Sumitomo Dainippon Pharma Key News
7.4 Intarcia Therapeutics
7.4.1 Intarcia Therapeutics Corporate Summary
7.4.2 Intarcia Therapeutics Business Overview
7.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Major Product Offerings
7.4.4 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.4.5 Intarcia Therapeutics Key News
7.5 Servier
7.5.1 Servier Corporate Summary
7.5.2 Servier Business Overview
7.5.3 Servier Non-Insulin Therapies for Diabetes Major Product Offerings
7.5.4 Servier Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.5.5 Servier Key News
7.6 Pfizer
7.6.1 Pfizer Corporate Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Non-Insulin Therapies for Diabetes Major Product Offerings
7.6.4 Pfizer Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.6.5 Pfizer Key News
7.7 Merck
7.7.1 Merck Corporate Summary
7.7.2 Merck Business Overview
7.7.3 Merck Non-Insulin Therapies for Diabetes Major Product Offerings
7.7.4 Merck Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.7.5 Merck Key News
7.8 Dong-A Pharmaceutical
7.8.1 Dong-A Pharmaceutical Corporate Summary
7.8.2 Dong-A Pharmaceutical Business Overview
7.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Major Product Offerings
7.8.4 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.8.5 Dong-A Pharmaceutical Key News
7.9 Luye Pharma Group
7.9.1 Luye Pharma Group Corporate Summary
7.9.2 Luye Pharma Group Business Overview
7.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Major Product Offerings
7.9.4 Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.9.5 Luye Pharma Group Key News
7.10 Eurofarma
7.10.1 Eurofarma Corporate Summary
7.10.2 Eurofarma Business Overview
7.10.3 Eurofarma Non-Insulin Therapies for Diabetes Major Product Offerings
7.10.4 Eurofarma Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.10.5 Eurofarma Key News
7.11 Geropharm
7.11.1 Geropharm Corporate Summary
7.11.2 Geropharm Business Overview
7.11.3 Geropharm Non-Insulin Therapies for Diabetes Major Product Offerings
7.11.4 Geropharm Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.11.5 Geropharm Key News
7.12 Alkem Labs
7.12.1 Alkem Labs Corporate Summary
7.12.2 Alkem Labs Business Overview
7.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Major Product Offerings
7.12.4 Alkem Labs Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.12.5 Alkem Labs Key News
7.13 SatRx
7.13.1 SatRx Corporate Summary
7.13.2 SatRx Business Overview
7.13.3 SatRx Non-Insulin Therapies for Diabetes Major Product Offerings
7.13.4 SatRx Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.13.5 SatRx Key News
7.14 Jiangsu Hansoh Pharmaceutical
7.14.1 Jiangsu Hansoh Pharmaceutical Corporate Summary
7.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
7.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Major Product Offerings
7.14.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.14.5 Jiangsu Hansoh Pharmaceutical Key News
7.15 Novo Nordisk
7.15.1 Novo Nordisk Corporate Summary
7.15.2 Novo Nordisk Business Overview
7.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Major Product Offerings
7.15.4 Novo Nordisk Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.15.5 Novo Nordisk Key News
7.16 Emisphere
7.16.1 Emisphere Corporate Summary
7.16.2 Emisphere Business Overview
7.16.3 Emisphere Non-Insulin Therapies for Diabetes Major Product Offerings
7.16.4 Emisphere Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.16.5 Emisphere Key News
7.17 Uni-Bio Science Group
7.17.1 Uni-Bio Science Group Corporate Summary
7.17.2 Uni-Bio Science Group Business Overview
7.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Major Product Offerings
7.17.4 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.17.5 Uni-Bio Science Group Key News
7.18 Takeda
7.18.1 Takeda Corporate Summary
7.18.2 Takeda Business Overview
7.18.3 Takeda Non-Insulin Therapies for Diabetes Major Product Offerings
7.18.4 Takeda Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.18.5 Takeda Key News
7.19 3SBio
7.19.1 3SBio Corporate Summary
7.19.2 3SBio Business Overview
7.19.3 3SBio Non-Insulin Therapies for Diabetes Major Product Offerings
7.19.4 3SBio Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.19.5 3SBio Key News
7.20 Jiangsu Hengrui Medicine
7.20.1 Jiangsu Hengrui Medicine Corporate Summary
7.20.2 Jiangsu Hengrui Medicine Business Overview
7.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Major Product Offerings
7.20.4 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.20.5 Jiangsu Hengrui Medicine Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
